This is the authors' abstract. We don't add key points for this paper.
The consensus panel has read the letter by Williams et al1 with great interest. In the letter, the authors shared their institutional experience with the use of per os perphenazine for postoperative nausea and vomiting (PONV) prophylaxis, and provided interesting insight into how per os perphenazine could be incorporated in multimodal PONV prophylaxis regimens. We acknowledge that the availability of intravenous (IV) perphenazine formulation is institution and country dependent; per os perphenazine on the other hand is readily available in most institutions. This certainly makes per os perphenazine a more viable option in several clinical settings. In addition, due to the availability of the generic formulation, per os perphenazine is likely a more cost-effective intervention. As we have discussed in the consensus guideline, with the increasing adoption of value-based remuneration in health care, the cost-effectiveness of interventions should be taken into consideration, especially when the intervention is applied on a large scale.2 However, as the authors have stated in their letter, there are currently very few published data on the use of per os perphenazine. In a commentary published by the authors, they have discussed the use of both IV and per os perphenazine, in addition to other pharmacological and nonpharmacological interventions.3 However, no control group was included. We identified one other retrospective study by Holder-Murray et al,4 which reported that perphenazine monotherapy had similar efficacy as aprepitant on early as well as late PONV. To the best of our knowledge, there are no randomized controlled trials that have investigated the efficacy of per os perphenazine. While it could be argued that available evidence on the efficacy of parenteral perphenazine does indirectly support the use of the per os formulation,5 the difference in pharmacokinetics, including onset time and bioavailability, needs to be considered, and may require further studies.6 The current consensus guideline expanded on the discussion regarding the practicalities of implementing effective PONV management pathways. As discussed, one of the biggest challenges to effective PONV management is maintaining adherence to the proposed algorithm.2,7 Administration of per os premedication in high-throughput presurgical units may be difficult due to staff and infrastructure limitations, and the organizational drive needed to implement such changes, and to ensure buy-in from all relevant stakeholders should not be underestimated. With the increasing adoption of per os aprepitant for higher-risk patients, more institutions have now set up systems to support the administration of per os antiemetic premedication. It is therefore likely that the administration of other per os premedications, including perphenazine, will be more easily implemented. The panel members would also like to thank the authors for their support of the general multimodal prophylaxis approach. The authors recommended administering perphenazine, dexamethasone, and ondansetron (P–D–O) in patients with low to medium PONV risk (including those with no risk factors), and adding a fourth agent in patients with high risk. In patients who have no risk factors, P–D–O is associated with an absolute risk reduction of 6%, and a number needed to treat of 16.7. While there is now extensive evidence on the safety of PONV prophylaxis, the panel members did have some reservations about routinely administering 3 antiemetics in patients with no risk factors, especially considering the small margin of benefit. It is also worth noting that, while combination of a 5-HT3 antagonist and dexamethasone has been extensively studied,8 very few studies have investigated the benefit and adverse effects associated with the addition a third antiemetic. As stated in the consensus statement, “the optimal multimodal prophylaxis regimen as well as the optimal number of antiemetics in combination therapies remains unclear due to lack of head-to-head comparisons.”2 Therefore, we feel that more studies are needed before the use of a third agent could be justified in lower-risk patients. In the higher-risk patients, per os perphenazine could prove to be a useful third or fourth agent, but more clinical data are needed to confirm its efficacy. We would like to thank the authors for sharing their valuable experience of using per os perphenazine for PONV prophylaxis. As the authors have discussed, the cost as well as the availability of per os perphenazine makes it a potentially valuable addition to the repertoire of PONV prophylaxis at clinician’s disposal. We would welcome the authors and other investigators to conduct further studies into the efficacy of per os perphenazine and look forward to their findings. Zhaosheng Jin, MBBS, BScTong J. Gan, MD, MBA, MHS, FRCADepartment of AnesthesiologyStony Brook Renaissance School of MedicineStony Brook, New York[email protected] Kumar G. Belani, MBBS, MSM Health FairviewMasonic Children’s HospitalUniversity of MinnesotaMinneapolis, Minnesota Sergio Bergese, MDStony Brook Renaissance School of MedicineStony Brook, New York Frances Chung, MBBSDepartment of Anesthesia and Pain ManagementToronto Western HospitalUniversity Health NetworkUniversity of TorontoOntario, Canada Pierre Diemunsch, MD, PhDUniversity Hospitals of Hautepierre and CMCOStrasbourg, France Ashraf S. Habib, MBBCh, MSc, MHSc, FRCADuke University School of MedicineDurham, North Carolina Anthony L. Kovac, MDUniversity of Kansas Medical CenterKansas City, Kansas Tricia A. Meyer, PharmD, MS, FASHP, FTSHPBaylor Scott & White Health-Temple Medical CenterTexas A&M College of Medicine Richard D. Urman, MD, MBABrigham and Women’s HospitalHarvard Medical SchoolBoston, Massachusetts Christian C. Apfel, MD, PhDUniversity of California San Francisco Medical CenterSan Francisco, California Sabry Ayad, MD, MBA, FASACleveland Clinic Lerner College of Medicineof Case Western Reserve UniversityOutcomes ResearchAnesthesiology InstituteCleveland Clinic Linda Beagley, MS, RN, CPAN, FASPANDepartment of Nursing EducationSwedish Hospital Part of NorthShoreChicago, Illinois Keith Candiotti, MDDepartment of Anesthesiology,Perioperative Medicine and Pain ManagementUniversity of MiamiMiller School of Medicine Marina Englesakis, BA (Hons), MLISHealth Sciences LibraryUniversity Health NetworkUniversity of TorontoOntario, Canada Traci L. Hedrick, MD, MScUniversity of Virginia Health SystemCharlottesville, Virginia Peter Kranke, MD, MBADepartment of AnaesthesiaUniversity Hospital of WuerzburgGermany Samuel Lee, CAAUniversity of Colorado HospitalAurora, Colorado Daniel Lipman, DNP, CRNAMD Anderson Cancer CenterHouston, Texas Harold S. Minkowitz, MDDepartment of Anesthesiology and Perioperative MedicineThe University of Texas MD Anderson Cancer CenterHouston, Texas John Morton, MD, MPH, MHADepartment of SurgeryYale School of MedicineNew Haven, Connecticut Beverly K. Philip, MDHarvard Medical SchoolBrigham and Women’s HospitalDepartment of Anesthesiology, and Perioperative and Pain MedicineBoston, Massachusetts
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: